PillCam SB3 Capsule- Feasibility Study
Launched by MEDTRONIC - MITG · Sep 11, 2011
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
* Purpose of study- To assess the performance of PillCam SB3 capsule in detecting small bowel lesions in patients
* Study design- Feasibility study
* Number of subjects- Up to 200
* Subject population- Patients with symptoms suggestive of small bowel disease and whom are eligible and indicated for SB capsule endoscopy
* No of centers- 4
* Duration of enrollment up to 12 months from IRB approval to enroll study patients
* Duration of follow-up 1 week after capsule procedure.
* Primary objectives To evaluate the performance of SB-3 system in patients as per physician questionnaire
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. Patient age is ≥ 18 years old,
- • 2. Patients with history suggestive and /OR symptoms suggestive of small bowel disease and whom are eligible and indicated for SB capsule endoscopy,
- • 3. Patient and/or legal guardian is able and agrees to sign the Informed Consent Form
- • Exclusion criteria
- • 1. Patient has dysphagia,
- • 2. Patient is known or is suspected to suffer from intestinal obstruction,
- • 3. Patient has known previous stricture/obstruction of the SB or colon,
- • 4. Patient has a cardiac pacemakers or other implanted electro medical devices, 5. Women who are either pregnant or nursing at the time of screening, who intend to be during the study period, or are of child-bearing potential and do not practice medically acceptable methods of contraception,
- • 6. Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule, 7. Patient has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator, 8. Patient has any condition, which precludes compliance with study and/or device instructions, 9. Patient suffers from life threatening conditions, 10. Patient is currently participating in another clinical study, 11. Patient has known slow gastric emptying time
Trial Officials
Samuel Adler, Prof
Principal Investigator
Medtronic - MITG
About Medtronic Mitg
Medtronic - Minimally Invasive Therapies Group (MITG) is a leading global sponsor focused on advancing minimally invasive surgical techniques and technologies to improve patient outcomes and optimize healthcare delivery. Committed to innovation and excellence, MITG develops a range of products and solutions that enhance surgical precision and efficiency, catering to a diverse array of medical conditions. Through rigorous clinical trials and research initiatives, Medtronic MITG aims to drive evidence-based practices in healthcare, ensuring that patients benefit from the latest advancements in minimally invasive procedures.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jerusalem, , Israel
Bucharest, , Romania
Pamplona, , Spain
Lund, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials